Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2

2(50.0%)

Phase 3

1(25.0%)

Phase 1

1(25.0%)

4Total

Phase 2(2)

Phase 3(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT05484154Phase 3Withdrawn

Efficacy and Safety Evaluation of 3K3A-APC in Ischemic Stroke

Role: lead

NCT05039268Phase 2Completed

3K3A-APC for Treatment of Amyotrophic Lateral Sclerosis (ALS)

Role: collaborator

NCT02222714Phase 2Completed

Safety Evaluation of 3K3A-APC in Ischemic Stroke

Role: lead

NCT01660230Phase 1Completed

Safety and Pharmacokinetics of Single and Multiple Ascending Doses of 3K3A-APC in Healthy Adult Volunteers

Role: lead

All 4 trials loaded